AR120030A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR120030A1 AR120030A1 ARP200102633A ARP200102633A AR120030A1 AR 120030 A1 AR120030 A1 AR 120030A1 AR P200102633 A ARP200102633 A AR P200102633A AR P200102633 A ARP200102633 A AR P200102633A AR 120030 A1 AR120030 A1 AR 120030A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- covalent bond
- heterocyclic compounds
- halo
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: R¹ es hidrógeno o C₁₋₆-alquilo; R², R³ y R⁴ se seleccionan independientemente de hidrógeno, un grupo de fórmula (2), C₁₋₆-alquilo, C₁₋₆-alcoxi, halo-C₁₋₆-alquilo, halo-C₁₋₆-alcoxi, halógeno y SF₅; R⁵, R⁶ y R⁷ se seleccionan independientemente de hidrógeno, halógeno y haloC₁₋₆-alquilo; X es CH o N; m y n son ambos 1; o m y n son ambos 0; A se selecciona de C₆₋₁₄-arilo y heteroarilo de 5 a 14 miembros; L¹ se selecciona de un enlace covalente, -CH₂-, -OCHRL-, -CHRLO- y -NHC(O)-; RL se selecciona de hidrógeno y C₁₋₆-alquilo; y B es (i) C₆₋₁₄-arilo y L² es un enlace covalente; o (ii) heterociclilo de 3 a 14 miembros o C₃₋₁₀-cicloalquilo; y L² se selecciona de un enlace covalente, -O- y -CH₂O-.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19199108 | 2019-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120030A1 true AR120030A1 (es) | 2022-01-26 |
Family
ID=68066569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102633A AR120030A1 (es) | 2019-09-24 | 2020-09-22 | Compuestos heterocíclicos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210094973A1 (es) |
| EP (1) | EP4034538A1 (es) |
| JP (1) | JP2022549446A (es) |
| KR (1) | KR20220069003A (es) |
| CN (1) | CN114401968A (es) |
| AR (1) | AR120030A1 (es) |
| AU (1) | AU2020354414A1 (es) |
| BR (1) | BR112022005472A2 (es) |
| CA (1) | CA3152213A1 (es) |
| CO (1) | CO2022002000A2 (es) |
| CR (1) | CR20220118A (es) |
| IL (1) | IL289594A (es) |
| MX (1) | MX2022002711A (es) |
| PE (1) | PE20220710A1 (es) |
| PH (1) | PH12022550472A1 (es) |
| TW (1) | TW202126663A (es) |
| WO (1) | WO2021058445A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| KR20220062515A (ko) | 2019-09-12 | 2022-05-17 | 에프. 호프만-라 로슈 아게 | Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물 |
| IL299664A (en) | 2020-09-03 | 2023-03-01 | Hoffmann La Roche | Heterocyclic compounds |
| CN118574807A (zh) | 2021-12-29 | 2024-08-30 | Psy治疗公司 | 抑制单酰基甘油脂肪酶（magl） |
| EP4469446A1 (en) * | 2022-01-25 | 2024-12-04 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| JP2025536386A (ja) * | 2022-10-24 | 2025-11-05 | エフ． ホフマン－ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| AU2013207252B2 (en) * | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| US10407407B2 (en) | 2015-05-21 | 2019-09-10 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
| LT3768684T (lt) * | 2018-03-22 | 2023-04-25 | F. Hoffmann-La Roche Ag | Oksazino monoacilglicerolio lipazės (magl) inhibitoriai |
| CA3104928A1 (en) * | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| CR20210056A (es) * | 2018-08-13 | 2021-03-02 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa |
-
2020
- 2020-09-22 AU AU2020354414A patent/AU2020354414A1/en not_active Abandoned
- 2020-09-22 PE PE2022000299A patent/PE20220710A1/es unknown
- 2020-09-22 AR ARP200102633A patent/AR120030A1/es not_active Application Discontinuation
- 2020-09-22 CN CN202080061840.2A patent/CN114401968A/zh active Pending
- 2020-09-22 KR KR1020227009452A patent/KR20220069003A/ko not_active Withdrawn
- 2020-09-22 WO PCT/EP2020/076347 patent/WO2021058445A1/en not_active Ceased
- 2020-09-22 US US17/027,976 patent/US20210094973A1/en not_active Abandoned
- 2020-09-22 BR BR112022005472A patent/BR112022005472A2/pt not_active Application Discontinuation
- 2020-09-22 CR CR20220118A patent/CR20220118A/es unknown
- 2020-09-22 CA CA3152213A patent/CA3152213A1/en active Pending
- 2020-09-22 JP JP2022518756A patent/JP2022549446A/ja active Pending
- 2020-09-22 PH PH1/2022/550472A patent/PH12022550472A1/en unknown
- 2020-09-22 EP EP20780981.5A patent/EP4034538A1/en not_active Withdrawn
- 2020-09-22 MX MX2022002711A patent/MX2022002711A/es unknown
- 2020-09-23 TW TW109132878A patent/TW202126663A/zh unknown
-
2022
- 2022-01-03 IL IL289594A patent/IL289594A/en unknown
- 2022-02-24 CO CONC2022/0002000A patent/CO2022002000A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210094973A1 (en) | 2021-04-01 |
| BR112022005472A2 (pt) | 2022-06-14 |
| AU2020354414A1 (en) | 2022-02-17 |
| CO2022002000A2 (es) | 2022-04-08 |
| TW202126663A (zh) | 2021-07-16 |
| KR20220069003A (ko) | 2022-05-26 |
| PE20220710A1 (es) | 2022-05-04 |
| EP4034538A1 (en) | 2022-08-03 |
| CR20220118A (es) | 2022-04-20 |
| WO2021058445A1 (en) | 2021-04-01 |
| JP2022549446A (ja) | 2022-11-25 |
| PH12022550472A1 (en) | 2023-02-27 |
| MX2022002711A (es) | 2022-03-22 |
| IL289594A (en) | 2022-03-01 |
| CA3152213A1 (en) | 2021-04-01 |
| CN114401968A (zh) | 2022-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120030A1 (es) | Compuestos heterocíclicos | |
| AR119943A1 (es) | Compuestos heterocíclicos | |
| AR119057A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR115949A1 (es) | Compuestos heterocíclicos | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| MX2022002039A (es) | Compuestos farmaceuticos. | |
| PE20200837A1 (es) | Compuestos macrociclicos derivados de diazaciclononadeca [1,2,3-c/d] indenos inhibidores de la proteina de diferenciacion celular de leucemia mieloide inducida (mcl-1) y composiciones farmaceuticas que los comprenden | |
| AR122517A1 (es) | Isoxazolidinas como inhibidores de ripk1 y usos de las mismas | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR119790A1 (es) | Compuestos de isoxazolina y su uso como agentes para el control de plagas | |
| AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
| AR116695A1 (es) | Los neuroesteroides y sus métodos de uso | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR118015A1 (es) | Compuestos herbicidas | |
| AR118613A1 (es) | Compuestos de oxadiazol para controlar o prevenir hongos fitopatogénicos | |
| DOP2024000077A (es) | Compuestos de cd73 | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR123583A1 (es) | Composiciones y métodos para el tratamiento de la infección por coronavirus | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma | |
| AR117366A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidin-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos | |
| AR126442A1 (es) | Inhibidores de map4k1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |